Could Aeterna Zentaris Inc (NASDAQ:AEZS) Skyrocket? The Stock Had Too Little Sellers

April 17, 2018 - By Darrin Black

The stock of Aeterna Zentaris Inc (NASDAQ:AEZS) registered a decrease of 5.35% in short interest. AEZS’s total short interest was 565,700 shares in April as published by FINRA. Its down 5.35% from 597,700 shares, reported previously. With 104,200 shares average volume, it will take short sellers 5 days to cover their AEZS’s short positions.

The stock decreased 2.01% or $0.03 during the last trading session, reaching $1.46. About 14,622 shares traded. Aeterna Zentaris Inc. (NASDAQ:AEZS) has declined 46.17% since April 17, 2017 and is downtrending. It has underperformed by 57.72% the S&P500.

Aeterna Zentaris Inc., a specialty biopharmaceutical company, engages in developing and commercializing novel treatments in oncology, endocrinology, and women's health. The company has market cap of $22.26 million. The companyÂ’s product pipeline includes Zoptrex, which completed Phase III clinical study for women with advanced, recurrent, or metastatic endometrial cancer, as well as in various phases for the treatment of ovarian and prostate cancer; and MACRILEN, which completed Phase III trial for use in the diagnosis of adult growth hormone deficiency. It currently has negative earnings. It is also developing an LHRH-disorazol Z conjugate, which is in pre-clinical development in oncology.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: